KR920019771A - α,β-불포화 케토락톤의 제조방법 - Google Patents

α,β-불포화 케토락톤의 제조방법 Download PDF

Info

Publication number
KR920019771A
KR920019771A KR1019920005662A KR920005662A KR920019771A KR 920019771 A KR920019771 A KR 920019771A KR 1019920005662 A KR1019920005662 A KR 1019920005662A KR 920005662 A KR920005662 A KR 920005662A KR 920019771 A KR920019771 A KR 920019771A
Authority
KR
South Korea
Prior art keywords
unsaturated
alkyl group
group
atom
represented
Prior art date
Application number
KR1019920005662A
Other languages
English (en)
Other versions
KR970003125B1 (ko
Inventor
류지 우에노
도미오 오다
Original Assignee
류지 우에노
가부시끼가이샤 알-테크 우에노
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 류지 우에노, 가부시끼가이샤 알-테크 우에노 filed Critical 류지 우에노
Publication of KR920019771A publication Critical patent/KR920019771A/ko
Application granted granted Critical
Publication of KR970003125B1 publication Critical patent/KR970003125B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

α,β-불포화 케토락톤의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 알칼리 금속 수소화물 및 아연 화합물하에서, 알킬 기의 3위치에 하나 이상의 할로겐 원자로 치환된 디메틸(2-옥소알킬)포스포네이트와 비시클로락톤 알데히드를 반응 시키는 것을 함유하는 α,β-불포화 케토락톤의 제조방법.
  2. 제1항에 있어서, 비시클로락톤 알데히드가 하기 일반식(1)로 표시되고, 디메틸(2-옥소알킬)포스포네이트가 하기 일반식(2)로 표시되는 α,β-불포화 케토락톤의 제조방법.
    〔식중 A는 히드록시 보호기를 나타내며 B는 단일 결합 또는 -CH2-를 나타낸다.〕
    〔식중 X1및 X2는 적어도 하나가 할로겐 원자이며, X1및 X2는 각기 수소원자 또는 할로겐 원자는 나타내고; R1은 탄수소 1~4의 알킬기를 나타내며; R2는 측쇄, 이중 결합, 알콕시 기, 페닐 기 또는 펜옥시 기 또는
    (식중 Y는 단일 결합 또는 원자이고; R3는 수소 또는 할로겐 원자, 또는 알킬 또는 할로겐화 알킬 기를 나타낸다.)를 갖을 수 있는 탄수소 1~10의 알킬기를 나타낸다.〕
  3. 제2항에 있어서, X1및 X2의 적어도 하나가 불소 원자인 α,β-불포화 케토락톤의 제조방법.
  4. 제1항에 있어서, α,β-불포화 케토락톤이 하기 반식(3)으로 표시되는 α,β-불포화 케토락톤의 제조방법.
    〔식중 A,X1,X2및 R2는 상기와 동일한 의미를 가지며 Z은 =CH-또는 -CH=CH-이다.〕
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920005662A 1991-04-04 1992-04-04 α,β-불포화 케토락톤의 제조방법 KR970003125B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP91-71483 1991-04-04
JP7148391 1991-04-04

Publications (2)

Publication Number Publication Date
KR920019771A true KR920019771A (ko) 1992-11-20
KR970003125B1 KR970003125B1 (ko) 1997-03-14

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005662A KR970003125B1 (ko) 1991-04-04 1992-04-04 α,β-불포화 케토락톤의 제조방법

Country Status (11)

Country Link
US (1) US5229529A (ko)
EP (1) EP0507625B1 (ko)
JP (1) JPH089608B2 (ko)
KR (1) KR970003125B1 (ko)
AT (1) ATE141921T1 (ko)
CA (1) CA2064481C (ko)
DE (1) DE69213067T2 (ko)
DK (1) DK0507625T3 (ko)
ES (1) ES2093776T3 (ko)
GR (1) GR3020903T3 (ko)
TW (1) TW197439B (ko)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327717T2 (de) * 1992-09-30 2000-06-21 R Tech Ueno Ltd Verfahren zur herstellung von alpha, beta-ungesättigten ketonen
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1789074A4 (en) * 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CN103755737A (zh) * 2006-02-07 2014-04-30 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
WO2010083597A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3107899B1 (en) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
CA3096838A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CA3131895A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US20230002740A1 (en) 2019-12-12 2023-01-05 Ignite Immunotherapy, Inc Variant oncolytic vaccinia virus and methods of use thereof
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
JP2023528416A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー，インク． 抗ａｂｃｇ２抗体及びそれらの使用
KR20230023032A (ko) 2020-07-14 2023-02-16 화이자 인코포레이티드 재조합 백시니아 바이러스
WO2022051390A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (ko) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
EP0219580B1 (en) * 1985-09-18 1989-11-29 The Upjohn Company Stereo-selective reduction
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
EP0394263B1 (en) * 1987-09-04 1994-03-16 The Upjohn Company Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
CA2064481A1 (en) 1992-10-05
KR970003125B1 (ko) 1997-03-14
DE69213067D1 (de) 1996-10-02
ATE141921T1 (de) 1996-09-15
TW197439B (ko) 1993-01-01
EP0507625B1 (en) 1996-08-28
JPH089608B2 (ja) 1996-01-31
ES2093776T3 (es) 1997-01-01
CA2064481C (en) 1996-12-24
GR3020903T3 (en) 1996-11-30
US5229529A (en) 1993-07-20
DE69213067T2 (de) 1997-01-16
EP0507625A1 (en) 1992-10-07
DK0507625T3 (da) 1996-09-16
JPH0592965A (ja) 1993-04-16

Similar Documents

Publication Publication Date Title
KR920019771A (ko) α,β-불포화 케토락톤의 제조방법
EA200500509A1 (ru) Способ получения производных тиоэфиров и его применение
TW262474B (ko)
MY107905A (en) Chemical process
KR840009092A (ko) 벤조푸란-또는 벤조피란-카르복사미드 유도체의 제조방법
RO82370B (ro) Procedeu pentru prepararea unor derivati de 9-aminodibenzopiran
KR830007686A (ko) 세팔로 스포린 유도체의 제조방법
RU96121801A (ru) Производные 22-тиавитамина d3
IE41108B1 (en) Amides and their use as fungicides
KR880005145A (ko) N-글리코릴네우라민산 함유 당지질 및 그 제조방법
KR830007484A (ko) 신규 신나모일-신나민산 유도체의 제조방법
KR860001789A (ko) 디히드로피리딘 유도체의 제조방법
BR8504501A (pt) Composto acaricida,processo para sua producao,composicao acaricida e processo para combater acaros
ES8304972A1 (es) Procedimiento de preparar derivados de acido carboxilico quetienen actividad antibacteriana.
KR840005713A (ko) [3.2.0]비시클로헵탄온 옥심 에테르류의 제조방법
KR870003074A (ko) 피라졸 유도체의 제조방법
KR860004030A (ko) 브로모디클로로 이미다졸 살충제의 제조방법
HUT38612A (en) Process for preparing intermediate products for the production of 16-phenoxy- and 16-(substituted phenoxy)-prostatriene acid-derivatives
HU904946D0 (en) Process for producing new imidazole derivatives
KR850008171A (ko) 시클릭 아졸일비닐 에테르의 제조방법
DK82583A (da) Furyloxazolyleddikesyrederivater og fremgangsmaader til fremstilling deraf
DE3268984D1 (en) Imidazolylcarboxylic acids, their derivatives and production
FR2595690B1 (fr) Procede de preparation d'aldehydes polyeniques
KR900006295A (ko) 할로게노-4-메틸피라졸류 및 그의 제조방법
AU2001284755A1 (en) Process for the preparation of alkyllithium compounds

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030801

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee